Oct 2 (Reuters) - Antisense Therapeutics Ltd (ANP) :
- Advised by FDA that full clinical hold for phase IIb clinical study of ATL1102 for multiple sclerosis has been lifted
- Co's application to conduct clinical trial of ATL1102 has been approved by Human Research Ethics Committee
News: ANP Antisense Therapeutics says FDA lifts hold for multiple sclerosis drug study
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.699M | |||
| Open | High | Low | Value | Volume |
| 0.9¢ | 0.9¢ | 0.8¢ | $1.301K | 156.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 6745374 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 1257781 | 6 |
View Market Depth
| Last trade - 15.56pm 22/07/2025 (20 minute delay) ? |
| PER (ASX) Chart |